A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Cisplatin
  • Lung Neoplasms
  • Taxoids

abstract

  • The combination of cisplatin at 80 mg/m2 with docetaxel 35 mg/m2 weekly or 75 mg/m2 every 3 weeks is no better tolerated than older chemotherapy regimens. The most common reason to stop chemotherapy was intolerable fatigue. These results suggest that the most common dose-limiting toxicities are attributable to the cisplatin, given similar problems were encountered whether the docetaxel was delivered as a single dose every 3 weeks or as a lower weekly dose.

publication date

  • July 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3715043

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e318074bbd0

PubMed ID

  • 17607120

Additional Document Info

start page

  • 638

end page

  • 44

volume

  • 2

number

  • 7